Duke Medical Center

Running trials

• Not yet recruiting

  Self-directed Mobile Mindfulness to Address ICU Survivors' Psychological Distress

  NCT07634419· Source

• Not yet recruiting

  Pilot Trial Utilizing β-hydroxy-β-methylbutyrate to Lower IGFBP7 Levels in People With ALS

  NCT07589764· Phase 1· Source

• Not yet recruiting

  A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma

  NCT07728188· Phase 3· Source

• Not yet recruiting

  A Study to Test Whether BI 3810477 Helps People With Idiopathic Pulmonary Fibrosis When Taken With or Without Standard Treatment

  NCT07926321· Phase 2· Source

• Not yet recruiting

  ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease

  NCT07850063· Phase 3· Source

• Recruiting

  Rehabilitation and Sex Therapy to Optimize Recovery After Prostate Cancer Treatment

  NCT07685249· Source

• Not yet recruiting

  Biomarker Testing to Predict Radiation-Related Heart Disease in Lung Cancer Patients

  NCT07869329· Source

• Recruiting

  The CATSINDO Trial - Clinical and Translational Study in Newly Diagnosed Osteosarcoma

  NCT07560826· Phase 2· Source

• Recruiting

  Upfront Chemotherapy With Radiation Therapy (CRT) Followed by Chemotherapy in Localized Esophageal Adenocarcinoma

  NCT07603375· Phase 2· Source

• Not yet recruiting

  Shared Decision Making to Address Racial Disparities in Oral Anticoagulation in NVAF

  NCT04956978· Source

• Recruiting

  A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

  NCT07293247· Phase 2· Source

• Not yet recruiting

  Duke Cardiometabolic Prevention Clinic's Impact on High-risk Cardiovascular Patients With Uncontrolled Risk Factors

  NCT07117695· Source

• Recruiting

  Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)

  NCT06917911· Phase 2· Source

• Recruiting

  Temporal Interference Brain Stimulation for Adults With Drug-Resistant Epilepsy Undergoing Stereo-EEG Monitoring

  NCT07764718· Source

• Recruiting

  A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia

  NCT07623200· Phase 3· Source

• Recruiting

  Tirzepatide in Idiopathic Intracranial Hypertension Trial

  NCT07191873· Phase 4· Source

• Recruiting

  BRiTE - Bispecific T Cell Engager for Patients With Glioblastoma

  NCT04903795· Phase 1· Source

• Recruiting

  Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial

  NCT07220187· Phase 3· Source

• Recruiting

  Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

  NCT07215910· Phase 3· Source

• Recruiting

  A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07518186· Phase 3· Source

• Recruiting

  B6 Administration for Levetiracetam-Associated Neurobehavioral Changes and Epilepsy

  NCT07271966· Source

• Recruiting

  A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer

  NCT07525206· Phase 3· Source

• Recruiting

  Study of INCA036978 in Participants With Myeloproliferative Neoplasms

  NCT07441694· Phase 1· Source

• Recruiting

  Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

  NCT07321652· Phase 3· Source

• Recruiting

  Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer

  NCT07493512· Phase 1· Source

• Recruiting

  A Study to Evaluate the Use of Resmetirom in Participants With MASLD and HIV

  NCT07143968· Phase 2· Source

• Recruiting

  Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma

  NCT07068074· Phase 3· Source

• Enrolling by invitation

  Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia

  NCT06773936· Phase 2· Source

• Recruiting

  A Gaucher Disease Gene Therapy Trial With FLT201

  NCT07223944· Phase 3· Source

• Recruiting

  A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma Patients

  NCT07549321· Phase 2/3· Source

• Recruiting

  Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

  NCT07421700· Phase 1/2· Source

• Recruiting

  Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

  NCT07491445· Phase 3· Source

• Recruiting

  Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial

  NCT07166406· Phase 3· Source

• Recruiting

  Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease

  NCT07404865· Phase 3· Source

• Recruiting

  Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer

  NCT06900595· Phase 2· Source

• Recruiting

  A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  NCT06842498· Phase 2· Source

• Recruiting

  Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial

  NCT06260891· Phase 2· Source

• Enrolling by invitation

  Comparative Study of High Performance Low-Cost Optical Coherence Tomography (Stage 1B, 2 and 3)

  NCT07425106· Source

• Recruiting

  Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD

  NCT07059091· Phase 2· Source

• Recruiting

  Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

  NCT07198074· Phase 3· Source

• Recruiting

  Intestinal Microbiome Transplant in ALS

  NCT07017946· Phase 1/2· Source

• Recruiting

  A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

  NCT07277231· Phase 3· Source

• Recruiting

  A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.

  NCT07235293· Phase 2· Source

• Active, not recruiting

  Horizon 360 Protocol for the Treatment of Paroxysmal Atrial Fibrillation With the Sphere-360™ Catheter and Affera™ Mapping and Ablation System (Horizon 360)

  NCT07308847· Source

• Recruiting

  TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

  NCT07190300· Phase 1/2· Source

• Recruiting

  A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)

  NCT07187973· Phase 1· Source

• Recruiting

  A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

  NCT07225946· Phase 3· Source

• Active, not recruiting

  A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome

  NCT07219602· Phase 3· Source

• Enrolling by invitation

  Liquid Biopsy in Glioblastoma Treated With Chemoradiation and an Oxygen Therapeutic

  NCT07417774· Source

• Recruiting

  A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

  NCT07226986· Phase 1/2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers36 recruiting
• Prostate cancer19 recruiting
• Lung cancer14 recruiting
• Acute myeloid leukemia12 recruiting
• Colorectal cancer11 recruiting
• Chronic lymphocytic leukaemia9 recruiting
• High blood pressure9 recruiting
• Acute lymphoblastic leukaemia8 recruiting
• Glioblastoma7 recruiting
• Pulmonary arterial hypertension7 recruiting
• Diffuse large B-cell lymphoma6 recruiting
• Melanoma6 recruiting
• Myeloproliferative neoplasms6 recruiting
• Ovarian cancer6 recruiting
• Sarcoma6 recruiting
• Sickle cell disease6 recruiting
• Bladder cancer5 recruiting
• Heart failure5 recruiting
• Myelodysplastic syndromes5 recruiting
• Pancreatic cancer5 recruiting
• Amyloidosis4 recruiting
• Endometrial cancer4 recruiting
• Gastric and esophageal cancer4 recruiting
• Kidney cancer4 recruiting
• Multiple myeloma4 recruiting
• Neuroendocrine tumours4 recruiting
• Pompe disease4 recruiting
• ALS (motor neurone disease)3 recruiting
• Alzheimer disease3 recruiting
• Atrial fibrillation3 recruiting
• Epilepsy3 recruiting
• Fatty liver disease (MASLD/MASH)3 recruiting
• Follicular lymphoma3 recruiting
• Frontotemporal dementia3 recruiting
• Idiopathic pulmonary fibrosis3 recruiting
• Mantle cell lymphoma3 recruiting
• Neuroblastoma3 recruiting
• Parkinson disease3 recruiting
• Stroke3 recruiting
• Cervical cancer2 recruiting
• Chronic myeloid leukaemia2 recruiting
• COPD2 recruiting
• Duchenne muscular dystrophy2 recruiting
• Gaucher disease2 recruiting
• Head and neck cancer2 recruiting
• Liver and biliary tract cancer2 recruiting
• Lupus (SLE)2 recruiting
• Metastatic breast cancer2 recruiting
• Systemic sclerosis (scleroderma)2 recruiting
• Triple-negative breast cancer2 recruiting
• Asthma1 recruiting
• Chronic kidney disease1 recruiting
• Coronary artery disease1 recruiting
• Crohn's disease1 recruiting
• Glaucoma1 recruiting
• HIV1 recruiting
• Hodgkin lymphoma1 recruiting
• Huntington's disease1 recruiting
• Lewy body dementia1 recruiting
• Mesothelioma1 recruiting
• Multiple sclerosis1 recruiting
• Obesity1 recruiting
• Sjögren's disease1 recruiting
• Thyroid cancer1 recruiting
• Ulcerative colitis1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Withdrawn

  Pharmacokinetics and Pharmacodynamics of Biologic Drugs in Obese Patients With Arthritis

  NCT04585711· Phase 1· Source

• Withdrawn

  Virtual Agent Feasibility in Oncology Patients (NTT Data)

  NCT06682013· Source

• Withdrawn

  Trimodality Approach of Low Dose iOnizing Radiation With or Without Neoadjuvant Pembrolizumab and Prostatectomy for Men With Intermediate/High Risk Prostate Cancer (TALON)

  NCT04569461· Phase 2· Source

• Completed

  Leveraging Exercise Stress Echocardiography for Heart Failure With Preserved Ejection Fraction

  NCT06927973· Source

• Completed

  LiveWell: Adapted DBT Skills Training for Metastatic Lung Cancer

  NCT06464562· Source

• Terminated

  Effects of Combination Medical Therapy Followed by BPA on Right Ventricular-PA Coupling and Hemodynamics in CTEPH

  NCT05140525· Phase 3· Source

• Recruiting

  A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

  NCT06667076· Phase 2· Source

• Completed

  A Study of the TactiFlex SE Catheter and Volt PFA Generator in Subjects With PAF:

  NCT06676072· Source

• Completed

  Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent

  NCT06322342· Phase 2· Source

• Completed

  RECOVER-ENERGIZE Platform Protocol

  NCT06404047· Source

• Completed

  Natural History Study of Exocrine Pancreatic Function in Infants With Cystic Fibrosis (CF)

  NCT06506773· Source

• Completed

  ROAR-DIGAP: A Widely Inclusive, Largely Virtual Pilot Trial Utilizing DIGAP (Deep Integrated Genomics Analysis Platform) To Personalize Treatments

  NCT06429059· Phase 2· Source

• Withdrawn

  Using Digital Health Technologies to Prevent Rapid Infant Weight Gain.

  NCT05265845· Source

• Completed

  Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

  NCT05934526· Phase 3· Source

• Completed

  Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma

  NCT06058793· Phase 3· Source

• Completed

  Multi-Institutional Transgender & Gender-Diverse Breast Cancer Study

  NCT06234488· Source

• Terminated

  Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis

  NCT06097260· Phase 2· Source

• Completed

  Glioblastoma Psychosocial Support Program

  NCT06038604· Source

• Withdrawn

  Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study

  NCT05356897· Phase 2· Source

• Recruiting

  A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

  NCT05730036· Phase 3· Source

• Completed

  Real-World Analysis of Belantamab Mafodotin Care Patterns in Patients With Relapsed and/or Refractory Multiple Myeloma

  NCT05986682· Source

• Completed

  Early Parkinson's Disease Monotherapy With CVN424

  NCT06006247· Phase 2· Source

• Completed

  A Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Polycythemia Vera (IMG-7289-CTP-203/MK-3543-004)

  NCT05558696· Phase 2· Source

• Withdrawn

  A Study to Investigate Leramistat in Patients With IPF

  NCT05951296· Phase 2· Source

• Completed

  Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection

  NCT05776225· Source

• Terminated

  CD40L Antagonism in Rheumatoid Arthritis (RA)

  NCT05306353· Phase 2· Source

• Completed

  Guideline Directed Medical Therapy (GDMT) Optimization and Adherence Longitudinal Study for Heart Failure.

  NCT05906745· Source

• Completed

  Optimizing In-hospital Use of Evidence-based Therapies for Patients With Cardio-Renal-Metabolic Disease

  NCT05781334· Source

• Completed

  Improving Screening and Therapy for Hispanic/Latinx at Risk for CKD

  NCT05734989· Source

• Terminated

  External Body Pressure in Heart Failure With Preserved Ejection Fraction

  NCT05764564· Source

• Completed

  The CARDIO-TTRansform Scintigraphy Sub-study

  NCT06073587· Source

• Withdrawn

  Effectiveness of Outpatient Intravenous Diuretic Therapy for Treatment of Worsening Heart Failure (OUTPATIENT-WHF)

  NCT05704595· Source

• Completed

  Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial

  NCT05590585· Phase 4· Source

• Withdrawn

  Phase II Clinical Trial of Clenbuterol in Adult Patients With Pompe Disease

  NCT04094948· Phase 2· Source

• Terminated

  A Study to Investigate LYL845 in Adults With Solid Tumors

  NCT05573035· Phase 1· Source

• Terminated

  AB1 in Adult Patients With Sickle Cell Disease (SCD)

  NCT05261711· Phase 1/2· Source

• Completed

  Systematic Evaluation of VNS Parameters

  NCT05395026· Source

• Recruiting

  Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC

  NCT05491525· Phase 2/3· Source

• Completed

  A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT05321069· Phase 3· Source

• Completed

  A Phase 1b/2 Trial of the Safety and Microbiological Activity of Bacteriophage Therapy in Cystic Fibrosis Subjects Colonized With Pseudomonas Aeruginosa

  NCT05453578· Phase 1/2· Source

• Completed

  Phase 2 Study of DKN-01 in Colorectal Cancer

  NCT05480306· Phase 2· Source

• Completed

  Vitamin E Dosing Study

  NCT04801849· Phase 2· Source

• Terminated

  CardioRenal Effects of SGLT2 Inhibition in Kidney Transplant Recipients

  NCT04906213· Phase 2· Source

• Completed

  High Dose Inspiratory Muscle Training in LOPD

  NCT05431127· Source

• Completed

  A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema

  NCT06850922· Phase 1/2· Source

• Recruiting

  Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer

  NCT05168163· Phase 2· Source

• Terminated

  A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)

  NCT05269355· Phase 2/3· Source

• Completed

  Expanding Technology-Enabled Nurse Delivered Chronic Disease Care

  NCT05120544· Source

• Completed

  Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)

  NCT04965597· Phase 2· Source

• Terminated

  A Pilot Study of a Micro-Organosphere Drug Screen Platform to Lead Care in Advanced Breast Cancer

  NCT04655573· Source

Trial sites

• Duke University Medical Center1 trial
• Duke Medical Center1 trial
• Duke University Medical Center620 trials
• Duke University Medical Center - 11581 trial
• Duke University Medical Center, Department of Hematologic Malignancies and Cellular Therapy2 trials
• Duke University Medical Center, Department of Medicine - Oncology1 trial
• Duke University Medical Center - Division of Hematologic Malignancies2 trials
• Duke University Medical Center: Division of Rheumatology and Immunology2 trials
• Duke University Medical Center - Duke Cancer Center12 trials
• Duke University Medical Center - Duke Cancer Centre1 trial
• Duke University Medical Center - Duke South1 trial
• Duke University Medical Center (DUMC)2 trials
• Duke University Medical Center /ID# 2562451 trial
• Duke University Medical Center /ID# 2596941 trial
• Duke University Medical Center /ID# 2676461 trial
• Duke University Medical Center /ID# 2679661 trial
• Duke University Medical Center /ID# 2681861 trial
• Duke University Medical Center /ID# 2793221 trial
• Duke University Medical Center /ID# 2794571 trial
• Duke University Medical Center /ID# 2834751 trial
• Duke University Medical Center, Investigational Chemotherapy Services2 trials
• Duke University Medical Center, lnvestigational Chemotherapy Service2 trials
• Duke University Medical Center (location of scans)2 trials
• Duke University Medical Center (Site 0016)1 trial
• Duke University Medical Center (Site 0017)1 trial
• Duke University Medical Center (Site 0050)1 trial
• Duke University Medical Center (Site 1026)4 trials
• Duke University Medical Center Site Number : 84000011 trial
• Duke University Medical Center- Site Number : 84000042 trials
• Duke University Medical Center- Site Number : 84000181 trial
• Duke University Medical Center- Site Number : 84000341 trial
• Duke University Medical Center-Site Number: 84000932 trials
• Duke University Medical Center - with Piedmont Health Services, Inc.1 trial
• Duke University Medical Centre1 trial
• Duke Univ. Med CNTR_Durham_21 trial
• Duke Univ Med Ctr1 trial
• Duke Univ Med Ctr /ID# 2428081 trial
• Duke Univ Medical Center6 trials
• Duke Univ. Medical Center/Duke Cancer Center1 trial
• The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center1 trial

Conditions

Diseases this institution publishes on or runs trials for.

• Heart failure252 works · 21 trials
• Stroke156 works · 4 trials
• Obesity133 works · 7 trials
• HIV112 works · 2 trials
• Lung cancer95 works · 64 trials
• Prostate cancer80 works · 39 trials
• Type 2 diabetes76 works · 6 trials
• Atrial fibrillation68 works · 8 trials
• Chronic kidney disease60 works · 8 trials
• Coronary artery disease45 works · 4 trials
• Glioblastoma45 works · 23 trials
• Epilepsy44 works · 5 trials
• Melanoma42 works · 20 trials
• Sarcoma34 works · 42 trials
• Sickle cell disease30 works · 19 trials
• Idiopathic pulmonary fibrosis28 works · 10 trials
• Glaucoma26 works · 1 trials
• Lupus (SLE)26 works · 3 trials
• Pompe disease24 works · 12 trials
• Kidney cancer24 works · 37 trials
• Osteoporosis20 works · 0 trials
• Metastatic breast cancer19 works · 15 trials
• Childhood cancers19 works · 130 trials
• Macular degeneration18 works · 2 trials
• Diabetic eye disease15 works · 1 trials
• Hypertrophic cardiomyopathy15 works · 1 trials
• Endometrial cancer14 works · 16 trials
• Neuroendocrine tumours13 works · 7 trials
• Head and neck cancer12 works · 10 trials
• Duchenne muscular dystrophy11 works · 4 trials